

Information for Colorado Prescribers of Prescription Drugs Rolvedon® (eflapragrastim-xnst)

(Last updated: 09/2026)

The Colorado Wholesale Acquisition Cost Disclosure Law (*Colorado House Bill 19-1131*) requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing.

The WAC prices listed below represent the Assertio Specialty Pharmaceuticals, LLC (“Assertio”) catalog or list price for the product sold to wholesalers, as reported to applicable pricing compendia at or around the date indicated. WAC does not reflect discounts, rebates and other reductions in price. The price paid by patients may differ from the WAC listed below and may be determined by the individual patient’s insurance coverage.

The prices below do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included. The pricing information listed does not imply safety or efficacy of the product or interchangeability with other products. Please refer to each product’s FDA-approved label and indication for further information.

NDC	MARKETED PRODUCT DESCRIPTION	PKG SIZE	UNIT OF MEASURE	WAC PER PKG
82497-0132-01	ROLVEDON (eflapragrastim-xnst) Injection 13.2mg/0.6mL	1	Single-Dose Prefilled Syringe	\$4,900

Under the Colorado Law, drug manufacturers are also required to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” The 2026 Colorado Select Drug List was used to determine similar generic drugs. If available, the names of at least three (3) generic prescription drugs from the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) for each marketed product are listed below.

NDC	PRODUCT DESCRIPTION	GENERIC #1	GENERIC #2	GENERIC #3
82497-0132-01	ROLVEDON (eflapragrastim-xnst) Injection 13.2mg/0.6mL	pegfilgrastim-jmdb	filgrastim	pegfilgrastim-jmdb

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch (www.fda.gov/medwatch) or call 1-800-FDA-1088.

For complete Prescribing Information of the marketed product, please visit the Assertio website (www.assertiotx.com).